SUZHOU, China, March 2, 2026
XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) for a Phase I/II registrational clinical trial of its allogeneic, off-the-shelf, iPSC-derived neuron progenitor cell therapy targeting Multiple System Atrophy – Parkinsonian Type (MSA-P). This milestone reinforces XellSmart’s expanding leadership in the development of induced pluripotent stem cell (iPSC)-based regenerative therapies for central nervous system (CNS) diseases, building on prior dual clearances for programs in Parkinson’s disease (PD), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS).
Advancing Regenerative Therapy for a Fatal Rare Disease
MSA-P is a rare, progressive, and fatal neurodegenerative disorder characterized by Parkinsonian motor symptoms, severe autonomic dysfunction, and abnormal α-synuclein aggregation leading to widespread neuronal degeneration. With a median survival of only 6 to 10 years after diagnosis, and no approved disease-modifying therapies globally, MSA-P represents a significant unmet medical need. Current standards of care, including dopaminergic drugs such as levodopa/carbidopa, provide limited and often suboptimal symptomatic relief compared to Parkinson’s disease.
XellSmart’s investigational therapy seeks to address disease pathology through a regenerative mechanism designed to restore dopamine secretion and promote neural circuit repair, potentially slowing or reversing disease progression rather than merely managing symptoms. By leveraging clinical-grade, universal, allogeneic iPSC-derived neuron progenitor cells, the company aims to provide a scalable and standardized treatment option capable of broad patient access.
Expanding Global Registrational Trial Portfolio
Advertisement
The MSA-P clearance represents XellSmart’s ninth IND approval across the U.S. and China, underscoring a strong regulatory track record for its CNS-focused pipeline. The company’s platform centers on off-the-shelf iPSC-derived cell products, manufactured under GMP-grade standards within its dedicated R&D and production facilities in Shanghai and Suzhou.
Ongoing and planned registrational studies include Phase I/II trials for Parkinson’s disease in both China and the U.S., including China’s first randomized, double-blind, controlled universal cell therapy study for early-onset PD. Additional trials target spinal cord injury and ALS, including an ALS program that previously received U.S. FDA Orphan Drug Designation. The planned MSA-P Phase I/II studies in China and the U.S. are expected to commence in 2026, further expanding XellSmart’s international clinical footprint.
Promising Clinical Signals in Parkinson’s Disease
The pipeline expansion into MSA-P builds on encouraging data emerging from XellSmart’s Parkinson’s disease registrational trials. More than a dozen patients with moderate-to-severe PD have undergone stereotactic neurosurgical transplantation of iPSC-derived dopaminergic neuron progenitors. Reported findings include no unexpected safety signals, improved motor function as reflected by MDS-UPDRS motor scores, prolonged “ON” state duration, and reduced “OFF” time. Brain PET imaging has suggested long-term survival and functional maturation of engrafted neurons, indicating potential durable therapeutic benefit.
These early outcomes support the feasibility and translational potential of iPSC-derived cell therapies for complex neurodegenerative disorders. By applying similar regenerative principles to MSA-P, XellSmart aims to broaden the clinical impact of its CNS cell therapy platform.
Strengthened Manufacturing and Market Confidence
Since its founding in 2021, XellSmart has secured sustained venture backing from leading investment firms, enabling rapid clinical progression and expansion of GMP-compliant manufacturing capacity. The company operates a 5,000-square-meter R&D and production infrastructure, integrating quality management systems designed to support global commercialization.
The consecutive regulatory clearances from both the FDA and NMPA serve as strong validation of the company’s scientific rigor and regulatory strategy. As regenerative medicine continues to reshape therapeutic paradigms in neurology, XellSmart’s advancements position it at the forefront of iPSC-derived cell therapy innovation for underserved CNS diseases, with the potential to redefine treatment options for patients facing devastating neurodegenerative conditions.
Source: XellSmart Biopharmaceutical press release
